TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: red blood cell folate acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Study Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CRC screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of ChAdOx1 85A vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Peripheral cortical and trabecular bone changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of atrial fibrillation episodes detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neuroimaging phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Expressions of interferon and T cell cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Non Relapse Mortality (NRM)
Endpoint domain: Mortality/survival
Primary endpoint: Objective response rate (PR+CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cormack Lehane (CL) grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Global Functioning Scale: Social (GFS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: The Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EAR Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative delirium diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MiniCog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clock Drawing Test (CDT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Three Word Recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Alzheimer Disease-8 Indonesia Questionnaire (AD-8 INA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Short Portable Mental Status Questionnaire (SPMSQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse events (AE) or serious AE information
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titer (GMT) and frequency of 4-fold or greater increases in serum hemagglutination inhibition (HAI) antibody titers against the influenza A/H5N1 virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of Tumor Involvement Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: level of pain measured by visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score in Canadian Occupational Performance Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Serum Alanine Aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Solicited Local Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited Systemic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of admission day
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Immunological effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of PU-H71
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of PU-H71
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Functional Status by the 6-minute Walk at 25 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic Blood Pressure at 25 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Blood Pressure at 25 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin-to-Skin Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: RR interval changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline Bone mineral density by DEXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of 1-year-recurrences
Endpoint domain: Mortality/survival
Primary endpoint: Area under the curve (AUC) of systemic acyclovir exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual time course profiles of 14C-radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of BI 671800 and its metabolite CD6384
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate and extent of excretion mass balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of lesions completely clear or with minimum residual signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood Pressure absolute Mean Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure standard Deviation of the Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the therapeutic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Perceived message effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma luteinizing hormone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma testosterone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Efficacy of aromatase inhibitors in reducing tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total reduced glutathione
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tissue Penetration of Omadacycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burden of primary caregivers
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Brain glucose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of LOFT therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of aristolochic-acid DNA adduct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of LF in febrile patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of LF in febrile patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of subjects achieving clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decolonization success/failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to Alleviation of COVID-19-related Symptoms by Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child body mass standard deviation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LESS score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Forced Expiratory Volume in 1 Second Percent Predicted (ppFEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in plasma potassium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in plasma glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentration of albuterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA Less Than 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of ovarian function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: pain in hand and elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hand function in daily living activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Amounts of intra-abdominal fat and total fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Ruxolitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Response Assessments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of Folate Deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Timing of Folate Deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence and incidence of anal HSIL
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative pancreatic fistula rate (PPF)
Endpoint domain: Adverse events/effects
Primary endpoint: Cytokines and chemokines associated with COVID-19 severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cellular subsets predicting COVID-19 severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in serum protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal weight assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: flow-mediated dilatation (FMD) of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Induction therapy outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of treatment successes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participant Safety as characterized by frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of renal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcomes Score (KOOS) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean FEV1 difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: obturator jerk occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Cessation of DNA shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seasonal influenza vaccine rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Gastric varice eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pro-BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transthoracic Echocardiography measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absolute Change in Water Content (Mean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in Water Content (Median)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moisture Retention (Mean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moisture Retention (Median)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residual platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients with complete or partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of moderate to severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant time spent in therapeutic INR range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Participant percent of INRs in the therapeutic INR range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participant's INR results resulting in a warfarin dose change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ADHD-Rating Scale (ADHD-RS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plasma holotranscobalamin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in knowledge questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HIV-related stigma among health facility staff
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HIV Knowledge Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Empathy and avoidance in treating patients living with HIV/AIDS (PLWHA)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dual task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: fNIRS measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain at Rest Difference Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain With Movement Difference Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in descriptive characterization of Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Expanded Disability Status Scale (EDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac and cerebral events
Endpoint domain: Adverse events/effects
Primary endpoint: Affective and Behavioral Responses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total recovery time of neuromuscular block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favorable neurologic outcome rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants with severe pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety of the combination of I3C + Sil
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic profile of I3C + Sil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Harris Hip Score (mHHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red cell folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of SARS-COV-2 virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pathologic Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Contrast-Induced Nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Contrast Induced Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of new T1-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of new T1-hypo-intensive lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ki67 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose (RPh2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: True positive and false positive detection of cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Procedural Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Safety (All SADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity and specificity of imaging techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients cooled to target within 1 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological outcome as indicated by NIHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rates of significant adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Grade and frequency of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Healthy Eating Index (HEI-2015) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TNF alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL 1beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-exercise Affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean During Exercise Affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-exercise Affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite Cognitive Function in Z-scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PTSD frequency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of catheter related venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time-average Steady State Testosterone Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain after kidney transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sitting, standing and stepping time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cooled radiofrequency ablation lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3-4 AEs
Endpoint domain: Adverse events/effects
Primary endpoint: change in general pain intensity during activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pain intensity during five times sit to stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pain intensity during five-stairs climbing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pain intensity during timed up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in impairment during active straight leg raise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in expectations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of metastatic lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of Donor Chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 - 12 Hours (AUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 12 - 24 Hours (AUC12 -24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response in Peak Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response in Trough Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mycological Cure at 48 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes